2018-07-11| Trials & Approvals

CFDA processes priority review of BGI’s BRCA1/2 gene testing kit

by GeneOnline
Share To

The BRCA1/2 gene mutation detection kit by the BGI Wuhan Ltd., a subsidiary of the Beijing Genomics Institute (BGI), received the priority reviewing notice from the Centre of Medical Device Evaluation, China Food and Drug Administration (CFDA) [1]. This BRCA1/2 gene testing kit is the first genetic test to be listed on the innovative medical device priority reviewing process.

By Joanne Shih

This BRCA1/2 gene mutation detection kit is performed with BGI’s in-house high-throughput sequencer and with combinatorial probe anchor synthesis (cPAS)-based sequencing method. This kit is designed for detecting germline variant of the exon and adjacent intron regions of BRCA1 and BRCA2 genes in patients with clinically diagnosed ovarian cancer and breast cancer.

The existence of BRCA1 and BRCA2 mutations is highly related to the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors when treating cancer. Therefore, being able to quantify the gene mutations in patients with BRCA-related cancers will allow clinicians to make more accurate treatment decision and advance the outcome of targeted therapy that uses PARP inhibitors.

If this BGI’s gene testing kit receive further approval from CFDA, it will be the first gene testing kit guiding the use of PARP inhibitors and may be beneficial to a large number of cancer patients.


  1. Centre of Medical Device Evaluation.CFDA:
  2. Okuma HS, Yonemori K. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. DOI. 10.1007/978-981-10-6020-5_13


© All rights reserved. Collaborate with us:
Related Post
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
Menarini’s Oral SERD Gains First-Ever FDA Approval for Breast Cancer
Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
Scroll to Top